Bioherent — Seed (estimated) · €2.9M

Bioherent, a University of Málaga spin-off founded in July 2021 that has built an integrated photonic biosensor for in vitro diagnosis of beta-lactam antibiotic allergies, raised a €2.9M round to run clinical validation and prepare market entry. CDTI committed €1,365,000 through its Innvierte programme alongside Bullnet Capital; no lead was stated.

Lead not disclosed RoundSeed (estimated) Announced21 Feb 2022 CityMálaga SectorHealthtech & Bio · Medtech / diagnostics Source

Something wrong? Suggest a correction →

The company

Investors 2

← All funding rounds

Start typing to search across everything.
↑↓ navigate↵ openesc close? shortcuts
Keyboard shortcuts
/ Ctrl K
Search
j k
Next or previous row
↵
Open the row
Ctrl ↵
Open it in a new tab
[ ]
Previous or next page
?
This list